SCHEMBL142250

SCHEMBL142250

COC(=O)c1cc(-c2ccccc2)nc2c1[nH]c1cccc(O)c12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR6 P51684 1/20 0.48
PLA2G2A P14555 2/20 0.46
MPL P40238 1/20 0.44
PDE10A Q9Y233 1/20 0.44
JAK2 O60674 2/20 0.42
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
GAA P10253 1/20 0.41
PKN1 Q16512 1/20 0.41
PKN2 Q16513 1/20 0.41
FTO Q9C0B1 1/20 0.40
HPGD P15428 1/20 0.40
DHODH Q02127 2/20 0.40
PIM3 Q86V86 1/20 0.40
LMNA P02545 1/20 0.40
TSHR P16473 1/20 0.40
MAPT P10636 1/20 0.39
THRB P10828 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL142302 0.85 PARP1 (0.47) CCR6JAK2PKN1PKN2DHODH
SCHEMBL138351 0.83 GABRP (0.44) PLA2G2APDE10AJAK2DHODH
SCHEMBL143234 0.73 JAK2 (0.49) PLA2G2APDE10AJAK2ALDH1A1KDM4E
SCHEMBL141099 0.72 JAK2 (0.58) PLA2G2AJAK2ALDH1A1KDM4EHPGD
SCHEMBL6622666 0.71 LMNA (0.50) MPLJAK2ALDH1A1KDM4EMEN1
SCHEMBL141522 0.70 JAK2 (0.80) PLA2G2AJAK2ALDH1A1KDM4EGAA
SCHEMBL142575 0.70 JAK2 (0.56) JAK2ALDH1A1KDM4EGAAHPGD
SCHEMBL142140 0.70 JAK2 (0.55) PLA2G2AJAK2KDM4EMAPTTHRB
SCHEMBL8617024 0.69 PDE10A (0.81) CCR6PLA2G2APDE10AALDH1A1KDM4E
SCHEMBL147675 0.69 GABRP (0.45) CCR6DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
EP-2370407-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 CCR6 1479/4885PLA2G2A 4509/4885MPL 221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.